SCHEMBL5547669

SCHEMBL5547669

CCCOC(=O)c1cccc(N[C]=O)c1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.64
LMNA P02545 4/20 0.55
HPGD P15428 3/20 0.55
SMN1; SMN2 Q16637 6/20 0.52
RAB9A P51151 5/20 0.52
NPC1 O15118 3/20 0.52
CYP1A2 P05177 1/20 0.52
CYP2C9 P11712 1/20 0.52
CYP2C19 P33261 1/20 0.52
TSHR P16473 2/20 0.51
KMT2A Q03164 1/20 0.51
MAPT P10636 4/20 0.51
TP53 P04637 2/20 0.51
MAPK1 P28482 2/20 0.51
HTR2B P41595 1/20 0.47
KDM4E B2RXH2 2/20 0.47
PFKFB3 Q16875 1/20 0.47
PFKFB4 Q16877 1/20 0.47
ESR1 P03372 1/20 0.46
CHRM1 P11229 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7575683 0.89 RAB9A (0.57) ALDH1A1LMNAHPGDSMN1; SMN2RAB9A
SCHEMBL5534870 0.88 ALDH1A1 (0.60) ALDH1A1LMNAHPGDSMN1; SMN2RAB9A
Hydrochloric Acid SCHEMBL6381116 0.82 ALDH1A1 (0.67) ALDH1A1LMNAHPGDSMN1; SMN2RAB9A
SCHEMBL5545348 0.82 ALDH1A1 (0.60) ALDH1A1LMNAHPGDSMN1; SMN2RAB9A
SCHEMBL2445250 0.82 RAB9A (0.59) ALDH1A1HPGDSMN1; SMN2RAB9ANPC1
SCHEMBL111664 0.81 LMNA (0.75) ALDH1A1LMNAHPGDSMN1; SMN2RAB9A
SCHEMBL5547676 0.80 ALDH1A1 (0.64) ALDH1A1LMNAHPGDSMN1; SMN2RAB9A
SCHEMBL9097843 0.79 LMNA (0.62) ALDH1A1LMNAHPGDSMN1; SMN2RAB9A
SCHEMBL5166192 0.79 LMNA (0.66) ALDH1A1LMNAHPGDSMN1; SMN2RAB9A
SCHEMBL6057282 0.79 LMNA (0.66) ALDH1A1LMNAHPGDRAB9ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 ALDH1A1 355/4885LMNA 4152/4885HPGD 3159/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.